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Receptor interacting protein kinase 1 (RIPK1) has important kinase-dependent and kinase-
independent scaffolding functions that activate or prevent apoptosis or necroptosis in a cell
context–dependent manner. The kinase activity of RIPK1 mediates hypothermia and
lethality in a mouse model of TNF-induced shock, reflecting the hyperinflammatory state of
systemic inflammatory response syndrome (SIRS), where the proinflammatory “cytokine
storm” has long been viewed as detrimental. Here, we demonstrate that cytokine and
chemokine levels did not predict survival and, importantly, that kinase-inactive
Ripk1D138N/D138N hematopoietic cells afforded little protection from TNF- or TNF/zVAD-
induced shock in reconstituted mice. Unexpectedly, RIPK1 kinase–inactive mice
transplanted with WT hematopoietic cells remained resistant to TNF-induced shock,
revealing that a nonhematopoietic lineage mediated protection. TNF-treated
Ripk1D138N/D138N mice exhibited no significant increases in intestinal or vascular
permeability, nor did they activate the clotting cascade. We show that TNF administration
damaged the liver vascular endothelium and induced phosphorylated mixed lineage kinase
domain-like (phospho-MLKL) reactivity in endothelial cells isolated from TNF/zVAD-treated
WT, but not Ripk1D138N/D138N, mice. These data reveal that the tissue damage present in
this SIRS model is reflected, in part, by breaks in the vasculature due to endothelial cell
necroptosis and thereby predict that RIPK1 kinase inhibitors may provide clinical benefit to
shock and/or sepsis patients.
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Introduction
The serine/threonine receptor interacting protein kinase 1 (RIPK1) 
plays a prominent role in proinflammatory and cell-survival sig-
naling by mediating optimal NF-κB and MAPK pathway activa-
tion downstream of TNF and TRIF-dependent TLRs. In addition 
to prosurvival signaling, RIPK1 can induce caspase-8–dependent 
apoptosis or caspase-independent necroptosis. Under conditions 
of caspase inhibition, the related RIPK1 and RIPK3 kinases inter-
act through their RIP homotypic interaction motif (RHIM), result-
ing in their auto- and trans-phosphorylation and RIPK3-mediated 
phosphorylation of the downstream pseudo-kinase mixed lineage 
kinase domain-like (MLKL). Phosphorylation of MLKL results 
in its oligomerization and translocation to the plasma mem-
brane. Activated MLKL mediates membrane permeabilization 
by as-yet-unclear mechanisms, leading to the release of damage- 
associated molecular patterns (DAMPs) and necroptosis (1, 2). 
ATP, HMGB1, heat shock proteins, and other DAMPs are recog-
nized by innate immune cells and can initiate or further ampli-
fy proinflammatory cytokine and chemokine production; thus, 
necroptosis is thought to be a more proinflammatory form of 
cell death compared with apoptosis (3). Necroptosis requires the 
kinase activities of RIPK1 and RIPK3 and can be activated down-
stream of death receptors (TNF, FAS, TRAIL), TLRs 3 and 4, type 
I or II interferon receptors (IFN-αR or IFN-γR), and the cytosolic 
viral sensor Z-DNA–binding protein 1 (ZBP1) (1, 2).
While the kinase activity of RIPK1 was initially thought to 
only be required for necroptotic death, recent in vitro and in vivo 
genetic data have shown a context- and cell type–dependent role 
for RIPK1 and its kinase activity in activating or suppressing both 
apoptosis and necroptosis. Ripk1–/– mice die at birth (4), but are 
rescued by codeletion of Casp8 and Ripk3, demonstrating that 
RIPK1 suppresses caspase-8–dependent apoptosis and RIPK3- 
dependent necroptosis during development (5–7). Furthermore, 
tissue-specific deletion of RIPK1 revealed that, in adult animals, 
RIPK1 primarily suppresses apoptosis in the intestine and necro-
ptosis in the skin and hematopoietic system (6, 8–10). Necro-
ptosis can proceed independently of RIPK1 in certain cell types, 
as RHIM-containing ZBP1 or TLR3/4 adapter TRIF can directly 
interact with RIPK3 (11–13). Since Ripk3–/– and Mlkl–/– mice are via-
ble (14–16), studies using these mice have implicated necroptosis 
in various inflammatory, neurodegenerative, and infectious dis-
eases (1, 2). RIPK1 kinase–dependent effects were initially interro-
gated using the small molecule inhibitor of RIPK1 kinase activity, 
Necrostatin-1 (Nec-1) (17, 18); however, interpreting these in vivo 
studies was limited by compound instability and off-target effects 
(19). The recent generation of kinase-inactive Ripk1D138N/D138N and 
Ripk1K45A/K45A mice has elucidated the role of RIPK1 kinase activity 
in necroptosis and in mouse models of acute and chronic inflam-
matory disease (20–22). Similarly to Ripk3–/– mice, RIPK1 kinase–
Receptor interacting protein kinase 1 (RIPK1) has important kinase-dependent and kinase-independent scaffolding functions 
that activate or prevent apoptosis or necroptosis in a cell context–dependent manner. The kinase activity of RIPK1 mediates 
hypothermia and lethality in a mouse model of TNF-induced shock, reflecting the hyperinflammatory state of systemic 
inflammatory response syndrome (SIRS), where the proinflammatory “cytokine storm” has long been viewed as detrimental. 
Here, we demonstrate that cytokine and chemokine levels did not predict survival and, importantly, that kinase-inactive 
Ripk1D138N/D138N hematopoietic cells afforded little protection from TNF- or TNF/zVAD-induced shock in reconstituted mice. 
Unexpectedly, RIPK1 kinase–inactive mice transplanted with WT hematopoietic cells remained resistant to TNF-induced 
shock, revealing that a nonhematopoietic lineage mediated protection. TNF-treated Ripk1D138N/D138N mice exhibited no 
significant increases in intestinal or vascular permeability, nor did they activate the clotting cascade. We show that TNF 
administration damaged the liver vascular endothelium and induced phosphorylated mixed lineage kinase domain-like 
(phospho-MLKL) reactivity in endothelial cells isolated from TNF/zVAD-treated WT, but not Ripk1D138N/D138N, mice. These data 
reveal that the tissue damage present in this SIRS model is reflected, in part, by breaks in the vasculature due to endothelial 
cell necroptosis and thereby predict that RIPK1 kinase inhibitors may provide clinical benefit to shock and/or sepsis patients.
RIP kinase 1–dependent endothelial necroptosis 
underlies systemic inflammatory response syndrome
Matija Zelic,1 Justine E. Roderick,1 Joanne A. O’Donnell,1 Jesse Lehman,1 Sung Eun Lim,1 Harish P. Janardhan,2  
Chinmay M. Trivedi,2 Manolis Pasparakis,3 and Michelle A. Kelliher1
1Department of Molecular, Cell and Cancer Biology, and 2Division of Cardiovascular Medicine and Department of Medicine, Program in Innate Immunity, University of Massachusetts Medical School,  
Worcester, Massachusetts, USA. 3Institute for Genetics, Centre for Molecular Medicine (CMMC), and Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD),  
University of Cologne, Cologne, Germany.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: July 14, 2017; Accepted: March 6, 2018.
Reference information: J Clin Invest. 2018;128(5):2064–2075. 
https://doi.org/10.1172/JCI96147.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 0 6 5jci.org   Volume 128   Number 5   May 2018
indicating that endothelial cell necroptosis contributes to increased 
vascular permeability, coagulation, and organ injury observed in 
TNF/zVAD-treated WT, but not RIPK1 kinase–inactive, mice.
Results
RIPK1 kinase activity regulates cytokine/chemokine production and 
neutrophil infiltration in response to TNF and TNF/zVAD. TNF 
shock mimics SIRS, which is thought to be driven by the proinflam-
matory cytokine storm. To assess the role of RIPK1 kinase activi-
ty in the cytokine storm, we analyzed proinflammatory cytokine 
and chemokine levels in the plasma of TNF- or TNF/zVAD-treat-
ed mice. Similar increases in CXCL1, CCL3, CCL4, CCL5, and 
IL-6 levels were observed in Ripk1D138N/D138N and WT mice at ear-
ly time points after TNF administration (Figure 1A). However, 
CXCL2 levels were consistently decreased in Ripk1D138N/D138N mice, 
suggesting that RIPK1 kinase activity may be required for opti-
mal TNF-induced CXCL2 production in vivo (Figure 1A). Cyto-
kine and chemokine levels were consistently reduced at 7 hours 
in RIPK1 kinase–inactive mice compared with TNF-treated WT 
mice (Figure 1A). The addition of the pan-caspase inhibitor zVAD 
sensitizes WT mice to TNF shock and decreases time to lethality 
inactive Ripk1D138N/D138N mice are protected from TNF- or TNF/
zVAD-induced acute shock; a model of systemic inflammatory 
response syndrome (SIRS) (21, 23).
SIRS can be triggered by sterile inflammation, including 
injury from burns, trauma, or acute pancreatitis, and upon infec-
tion, can lead to sepsis and septic shock (24, 25). It has long 
been hypothesized that the “cytokine storm” drives shock, with 
excess production of proinflammatory cytokines such as TNF-α 
and IL-1β triggering vascular dysfunction and organ injury (24). 
However, attempts over the last couple of decades to block TNF 
or IL-1R signaling in septic patients have largely failed to provide 
a survival benefit (26–28).
Although necroptosis has recently been implicated in the 
pathogenesis of TNF-induced shock and SIRS (20–23), the pre-
cise cell types undergoing necroptosis and the relative contribu-
tion of the cytokine storm remain unclear. Here, we demonstrate 
that proinflammatory cytokine/chemokine levels do not correlate 
with hypothermia or survival in this mouse SIRS model and that 
nonhematopoietic RIPK1 kinase–inactive cells mediate resistance 
to TNF- or TNF/zVAD-induced shock. Additionally, we show that 
WT liver endothelial cells undergo MLKL activation and cell death, 
Figure 1. Ripk1D138N/D138N mice exhibit impaired cytokine and chemokine production in response to TNF and TNF/zVAD administration in vivo. (A) Plasma 
cytokine and chemokine levels in WT and Ripk1D138N/D138N mice 2 and 7 hours after i.v. TNF administration (n = 8–9) or (B) 2 hours after i.v. TNF or TNF/zVAD 
administration (n = 6–9). TNF-induced levels are repeated from A. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, 
2-tailed Student’s t test (A) or 2-way ANOVA with post hoc Tukey’s test (B).
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Ripk1D138N/D138N mice and stimulated them in vitro with TNF or TNF/
zVAD. We found that the kinase activity of RIPK1 was required for 
the induction and production of Cxcl1, Cxcl2, and Il6, but not Ccl5, 
in response to TNF/zVAD (Supplemental Figure 1, A and B; sup-
plemental material available online with this article; https://doi.
org/10.1172/JCI96147DS1). Interestingly, Ripk1D138N/D138N BMDMs 
also exhibited reduced Cxcl2 expression and secretion when treat-
ed with TNF alone, indicating that RIPK1 kinase activity is neces-
sary for optimal TNF-induced Cxcl2 upregulation in vitro (Supple-
mental Figure 1, A and B). Thus, RIPK1 kinase activity contributes 
to TNF- and TNF/zVAD-induced cytokine and chemokine tran-
scription in primary BMDMs in vitro and may be responsible for 
reduced cytokine and chemokine levels during TNF shock in vivo.
To determine whether reductions in cytokine/chemokine lev-
els in RIPK1 kinase–inactive mice result in decreased inflammato-
ry cell mobilization and infiltration, we analyzed peripheral blood, 
bone marrow, spleen, lung, and liver for evidence of inflammatory 
macrophage and neutrophil recruitment in response to TNF or 
TNF/zVAD administration. Systemic TNF administration mobi-
lized inflammatory macrophages and neutrophils from the spleens 
and bone marrow of WT and Ripk1D138N/D138N mice (Figure 2, A and 
B). However, more neutrophils were detected in Ripk1D138N/D138N 
spleen and bone marrow compared with those of TNF-treated WT 
mice (Figure 2, A and B). TNF-induced inflammatory monocyte 
(21, 23, 29). To ascertain whether TNF/zVAD sensitization cor-
relates with increased proinflammatory cytokine levels, we com-
pared TNF- and TNF/zVAD-induced plasma cytokine/chemokine 
levels at 2 hours. Interestingly, WT mice treated with TNF/zVAD 
exhibited significantly elevated plasma cytokine and chemokine 
levels compared with those who received treatment with TNF 
alone, especially for CXCL2, CCL3, CCL4, and IL-6 (Figure 1B). 
IL-1β and IL-17α levels, which are found to be increased in septic 
patients (30, 31), were elevated systemically in WT mice treat-
ed with TNF/zVAD, but not TNF (Figure 1B). While the addition 
of zVAD amplified cytokine and chemokine levels in WT mice, 
Ripk1D138N/D138N mice exhibited significantly lower plasma levels of 
proinflammatory cytokines and chemokines (Figure 1B). Overall, 
these results suggest that the plasma proinflammatory cytokine/
chemokine levels correlate with the kinetics of hypothermia and 
lethal shock. Furthermore, these data suggest that TNF/zVAD sen-
sitizes mice to necroptotic death in vivo, which is postulated to be 
proinflammatory due to DAMP release (3).
Recently, the kinase activity of RIPK1 has been implicated in 
the transcriptional regulation of certain cytokines and chemokines 
in response to TNF/zVAD or LPS/zVAD treatment (22, 32–34). To 
test whether RIPK1 kinase is required for transcriptional activa-
tion of inflammatory cytokines/chemokines, we isolated prima-
ry bone marrow–derived macrophages (BMDMs) from WT and 
Figure 2. Impaired recruitment of Ripk1D138N/D138N inflammatory cells in response to TNF or TNF/zVAD administration. (A and B) Splenocytes and bone 
marrow cells were stained with antibodies, analyzed by flow cytometry, and the number of inflammatory (Inflam.) monocytes/macrophages or neutrophils 
determined. The number of cells for WT and Ripk1D138N/D138N mice left untreated (Unt.) or treated with TNF (7 hours) or TNF/zVAD (4 hours) (n = 3–5) is shown. 
(C) The number of inflammatory monocytes or neutrophils in peripheral blood of WT and Ripk1D138N/D138N mice left untreated or treated with TNF (7 hours) or 
TNF/zVAD (4 hours) is shown (n = 3–5). (D and E) The number of inflammatory macrophages or neutrophils in lung and liver of WT and Ripk1D138N/D138N mice 
left untreated or treated with TNF (7 hours) or TNF/zVAD (4 hours) (n = 4–5) is shown. *P < 0.05; **P < 0.01; ***P < 0.001, 2-tailed Student’s t test.
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by transplanting WT or Ripk1D138N/D138N bone marrow cells into lethal-
ly irradiated syngeneic recipients (Figure 3A). Two months after 
reconstitution, RIPK1 kinase–inactive donor-derived cells repopu-
lated irradiated recipients as effectively as WT cells (Supplemental 
Figure 2, A–C), indicating that RIPK1 kinase activity does not con-
tribute to the cell-intrinsic survival function of RIPK1 in hematopoi-
etic cells (6, 10). We next tested the TNF response, and as expected, 
WT controls developed hypothermia in response to TNF (Figure 
3B) or TNF/zVAD (Figure 3D) administration and succumbed to 
shock. Unexpectedly, Ripk1D138N/D138N→WT mice succumbed with 
kinetics similar to those of WT→WT controls in response to TNF 
(Figure 3C) or TNF/zVAD (Figure 3E) administration. Interestingly, 
WT→Ripk1D138N/D138N mice were completely protected from TNF- or 
TNF/zVAD-induced shock (Figure 3, B–E). These data reveal that a 
nonhematopoietic Ripk1D138N/D138N lineage or lineages mediate pro-
tection from TNF- and TNF/zVAD-induced shock.
Cytokine levels and neutrophil infiltration do not correlate with 
survival. To further examine any contribution of the cytokine storm, 
we measured proinflammatory cytokine and chemokine levels in 
the plasma of TNF-treated reconstituted mice. In a manner compa-
rable to what we observed in nonreconstituted mice, TNF treatment 
similarly upregulated cytokine and chemokine levels at 2 hours in 
all the bone marrow chimeras, notably revealing that RIPK1 kinase 
activity does not appear to regulate cytokine transcription during 
TNF shock (Figure 4A). While cytokine/chemo kine levels were 
further elevated in WT controls 7 hours after TNF administration, 
recruitment to the blood and similar numbers of inflammatory 
monocytes/macrophages were detected in the lungs and liver of 
TNF-treated WT and Ripk1D138N/D138N mice (Figure 2, C–E). Consis-
tent with reduced levels of the neutrophil chemoattractant CXCL2 
(Figure 1A), TNF-treated Ripk1D138N/D138N mice exhibited decreased 
neutrophil mobilization from the bone marrow and spleen into the 
blood. However, inflammatory cell infiltration in lung and liver 
was similar for WT and Ripk1D138N/D138N mice treated with TNF (Fig-
ure 2). Although TNF/zVAD administration to WT mice resulted in 
a more robust cytokine/chemokine response (Figure 1B), this did 
not result in significant increases in inflammatory cell mobiliza-
tion into blood, lung, or liver compared with treatment with TNF 
only (Figure 2, C–E). Although TNF/zVAD treatment significant-
ly increased neutrophil numbers in the spleen and bone marrow, 
Ripk1D138N/D138N mice exhibited reduced neutrophil infiltration into 
lung and liver (Figure 2). Activated neutrophils release proteases 
and reactive oxygen species, thereby damaging organs and further 
increasing cytokine production (35). Thus, the reduced cytokine/
chemokine levels and impaired neutrophil mobilization observed 
in TNF- and TNF/zVAD-treated Ripk1D138N/D138N mice may be 
responsible for the protection.
RIPK1 kinase activity in a nonhematopoietic lineage is responsible 
for TNF- and TNF/zVAD-induced lethality. These data suggest that 
inflammatory cells mediate organ damage and predict that RIPK1 
kinase–inactive hematopoietic cells provide protection in this SIRS 
model. To test this, we generated reciprocal bone marrow chimeras 
Figure 3. Nonhematopoietic RIPK1 kinase–inactive cells protect against TNF- and TNF/zVAD-induced shock. (A) Experimental design. IR, irradiation. 
Body temperature (B and D) and Kaplan-Meier survival curves (C and E) after TNF- (B and C) or TNF/zVAD-induced shock (D and E) are depicted for 
lethally irradiated WT and Ripk1D138N/D138N mice reconstituted with WT or Ripk1D138N/D138N bone marrow cells. Data are shown as mean ± SEM. ***P < 0.001; 
****P < 0.0001, Mantel-Cox test.
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hematopoietic lineages, whereas a lack of RIPK1 kinase activity in 
a nonhematopoietic lineage provides protection.
We observed similar mobilization and infiltration of inflam-
matory monocytes/macrophages and neutrophils into the blood, 
lungs, and liver of all TNF-treated reconstituted groups (Figure 4, 
B–D). In fact, more inflammatory macrophages and neutrophils 
infiltrated the lung and liver, respectively, of protected WT→ 
Ripk1D138N/D138N chimeras compared with sensitive Ripk1D138N/D138N 
→WT mice. These data suggest that a lack of RIPK1 kinase activity 
in either hematopoietic or nonhematopoietic cells does not abro-
gate TNF-induced inflammatory cell recruitment.
TNF-induced increases in intestinal permeability require RIPK1 
kinase activity. Since RIPK1 kinase–inactive hematopoietic cells 
proved not to be the critical lineage mediating protection from 
TNF shock (Figure 3), we examined other lineages affected by 
TNF administration. TNF receptor 1 (TNFR1) expression levels in 
intestinal epithelial cells have been shown to correlate with TNF- 
induced increases in intestinal permeability and overall lethality 
in mice (36, 37). To assess intestinal permeability, we measured 
the plasma fluorescence levels of orally gavaged FITC-conjugated 
unexpectedly, both sensitive Ripk1D138N/D138N→WT and resistant 
WT→Ripk1D138N/D138N chimeras exhibited significant decreases in 
cytokine/chemokine levels (Figure 4A), demonstrating that cyto-
kine/chemokine levels do not predict survival. These data also 
suggest that RIPK1 kinase–inactive hosts lack a secondary trigger, 
potentially provided by the necroptosis of nonhematopoietic cells, 
that may amplify proinflammatory signaling by feeding back on 
necroptosis-competent WT hematopoietic cells. Additionally, the 
data suggest that, in sensitive Ripk1D138N/D138N→WT mice, DAMPs 
released from necroptotic WT nonhematopoietic cells fail to 
amplify cytokine/chemokine levels to levels observed in WT→WT 
mice, potentially because Ripk1D138N/D138N hematopoietic cells do 
not undergo necroptosis (Figure 4A). Furthermore, we found 
that TNF/zVAD treatment resulted in greater increases in cyto-
kine/chemokine levels at 2 hours in both sensitive Ripk1D138N/D138N 
→WT mice and resistant WT→Ripk1D138N/D138N chimeras compared 
with treatment with TNF only (Supplemental Figure 3), suggesting 
that necroptosis amplifies proinflammatory cytokine/chemokine 
production. Additionally, maximal cytokine/chemokine produc-
tion requires RIPK1 kinase activity in both hematopoietic and non-
Figure 4. Proinflammatory cytokines and inflammatory cell recruitment do not correlate with survival in a TNF-induced model of shock. (A) Plasma 
cytokine and chemokine levels in reconstituted mice 2 and 7 hours after i.v. TNF administration (n = 4–7). Graphs depicting the number of inflammatory 
monocytes/macrophages and neutrophils in the blood (B), lungs (C), or liver (D) of lethally irradiated WT and Ripk1D138N/D138N mice reconstituted with WT or 
Ripk1D138N/D138N bone marrow cells as measured by flow cytometry 8 hours after systemic TNF administration (n = 4–5). Data are shown as mean ± SEM.  
*P < 0.05; **P < 0.01; ***P < 0.001, 2-way (A) or 1-way ANOVA with post hoc Tukey’s test (B–D).
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dextran beads following TNF administration. WT mice exhibited 
a significant increase in intestinal permeability, but no increase in 
intestinal permeability was observed in Ripk1D138N/D138N mice upon 
TNF administration (Figure 5A). Although Ripk1D138N/D138N mice 
were protected from TNF-induced lethality, cleaved caspase-3 
staining revealed similar numbers of apoptotic colonocytes in 
WT and RIPK1 kinase–inactive mice (Supplemental Figure 4B). 
Interestingly, WT mice had slightly elevated numbers of cleaved 
caspase-3–positive cells in the ileum, suggesting that some intes-
tinal epithelial cells may undergo RIPK1 kinase–mediated apop-
tosis in response to TNF (Supplemental Figure 4A). Importantly, 
TNF/zVAD administration similarly suppressed ileal and colonic 
apoptosis in WT and Ripk1D138N/D138N mice, suggesting that intesti-
nal apoptosis is not responsible for the lethality observed in WT 
mice (Supplemental Figure 4, A and B). Since intestinal leakage 
could disseminate the gut microflora systemically, activate TLR 
signaling, and amplify inflammatory cytokine production (37), 
we quantified bacterial growth in spleen and liver lysates from 
untreated and TNF-treated WT and Ripk1D138N/D138N mice (Figure 
5B). Although TNF augmented intestinal permeability, we could 
not detect an increase in bacterial colonies from spleen and liver 
lysates when WT mice were treated with TNF (Figure 5B), indicat-
ing that changes in intestinal permeability were not sufficient to 
induce systemic bacteremia in this i.v. TNF shock model.
RIPK1 kinase activity is required for TNF-induced increases in 
vascular permeability and clotting. In addition to increasing intes-
tinal epithelial permeability, TNF stimulates vascular permeabil-
ity and endothelial activation by upregulating the expression of 
adhesion molecules and by stimulating cytokine and chemokine 
production (38, 39). To quantitatively assess TNF-induced vascu-
lar permeability changes, we measured the extravasation of Evans 
blue dye. TNF administration induced significant increases in 
vascular permeability, resulting in Evans blue dye leakage into the 
lungs and liver of WT mice, while Ripk1D138N/D138N mice exhibited 
no detectable increase in vascular permeability (Figure 5C). Addi-
tionally, WT mice exhibited activation of the extrinsic coagulation 
cascade, as evidenced by significant increases in plasma tissue 
factor levels following TNF or TNF/zVAD administration (Figure 
5D). To determine whether RIPK1 kinase activity in endothelial 
cells was responsible for the increased vascular permeability, we 
examined these vascular parameters in chimeric mice. WT→WT 
and Ripk1D138N/D138N→WT chimeras, which remain sensitive to TNF 
shock, displayed increased vascular permeability in their lungs and 
liver (Figure 5E) and exhibited elevated tissue factor levels during 
TNF-induced shock (Figure 5F). Notably, WT→Ripk1D138N/D138N 
mice, which were protected from TNF-induced shock, showed no 
significant increase in TNF-induced vascular permeability and 
maintained basal levels of plasma tissue factor in response to TNF 
(Figure 5, E and F). These data suggest that RIPK1 kinase activ-
ity in endothelial cells is responsible for TNF-induced increases 
in vascular permeability and coagulation. Consistent with these 
data, histological examination of the livers in TNF- and TNF/
Figure 5. Nonhematopoietic RIPK1 
kinase–inactive cells protect against 
TNF-induced intestinal and vascular 
hyperpermeability and coagulation. (A) 
FITC-labeled dextran beads were adminis-
tered to WT and Ripk1D138N/D138N mice by oral 
gavage 2 hours after TNF injection. Blood 
was isolated by cardiac puncture and the 
levels of FITC-dextran in plasma measured 
by fluorometry (n = 4–7). (B) Bacterial 
growth in spleen and liver lysates isolated 
from untreated WT and Ripk1D138N/D138N  
mice or 10 hours after injection with 15 μg 
TNF (n = 3–6). (C) WT and Ripk1D138N/D138N 
mice were injected with TNF and Evans 
blue dye, organs were collected, and the 
amount of dye extracted from the lung and 
liver was measured by spectrophotometry 
(n = 7–8). (D) Tissue factor levels were 
determined by ELISA in the plasma of TNF- 
or TNF/zVAD-treated WT and Ripk1D138N/D138N  
mice (n = 3–7). (E) WT and Ripk1D138N/D138N 
reconstituted mice were injected with TNF 
and Evans blue dye, and the amount of 
dye extracted from the lung and liver was 
measured by spectrophotometry (n = 6–7). 
(F) Tissue factor levels in the plasma of 
reconstituted WT and Ripk1D138N/D138N mice 
treated with TNF (n = 3–5). Data are shown 
as mean ± SEM. *P < 0.05; **P < 0.01, 
2-way ANOVA with post hoc Tukey’s test 
(A and C), 2-tailed Student’s t test (D), or 
1-way ANOVA with post hoc Tukey’s test 
(E and F).
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zVAD-treated WT mice revealed significant increases in blood 
vessel clotting compared with that in untreated controls (Figure 
6, A and B). We observed neutrophil and erythrocyte adhesion 
to the endothelium and leakage of erythrocytes and leukocytes 
into the extravascular space due to increased vascular permea-
bility (Figure 6A). Although we observed some evidence of neu-
trophil/erythrocyte adhesion and clotting in the TNF- and TNF/
zVAD-treated Ripk1D138N/D138N liver sections, there was a significant 
reduction in clotting in the liver blood vessels (Figure 6, A and B). 
To quantify clotting function, we performed a prothrombin time 
test. Blood isolated from TNF-treated WT mice took significantly 
longer to clot compared with that of RIPK1 kinase–inactive mice 
(Figure 6C), suggesting that coagulation factors were consumed 
in TNF-treated WT mice due to activation of the extrinsic clotting 
cascade. These data demonstrate that lack of RIPK1 kinase activi-
ty in endothelial cells protects from TNF- and TNF/zVAD-induced 
increases in vascular permeability and coagulation.
TNF-induced adhesion molecule expression does not require 
RIPK1 kinase activity. We hypothesized that RIPK1 kinase activity 
may regulate vascular permeability by directly mediating endo-
thelial cell activation. To test this possibility, we isolated primary 
endothelial cells from the lungs of WT and Ripk1D138N/D138N mice 
and measured Icam1, Vcam1, Sele, and Selp mRNA levels via real-
time quantitative PCR. We detected no significant differences 
in TNF-induced Icam1, Vcam1, Sele, and Selp upregulation in WT 
and Ripk1D138N/D138N primary lung endothelial cells, indicating that 
Figure 6. RIPK1 kinase–inactive mice are protected from TNF- or TNF/zVAD-induced coagulation and breaks in the liver endothelium, and from TNF/
zVAD-induced liver endothelial cell necrosis. (A) Representative images of H&E-stained liver sections from WT or Ripk1D138N/D138N mice left untreated 
or injected i.v. with TNF or TNF/zVAD (n = 3–4 mice). Scale bars: 100 μm (×10); 50 μm (×40). (B) Quantification of clotting observed in liver blood vessels 
of mice shown in A. (C) Citrated plasma was isolated from WT and Ripk1D138N/D138N mice 7 hours after TNF administration, and clot formation time was 
measured by the prothrombin time test (n = 4 mice). (D) Representative images of endomucin-stained liver sections from untreated or TNF- or TNF/
zVAD-treated WT and Ripk1D138N/D138N mice (n = 3–4 mice). Scale bars: 50 μm (×40). (E) WT and Ripk1D138N/D138N liver endothelial cells were isolated from 
untreated or TNF/zVAD-treated mice. A representative Western blot showing protein lysates probed with antibodies to phospho-MLKL, MLKL, and 
ERK1/2 is depicted. Lysates were generated and analyzed from 14 WT and 8 Ripk1D138N/D138N TNF/zVAD-treated mice. Data are shown as mean ± SEM.  
**P < 0.01, 2-tailed Student’s t test.
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Due to a lack of reliable measures of necroptotic death in mice, 
we isolated primary liver endothelial cells from TNF- and TNF/
zVAD-treated WT and Ripk1D138N/D138N mice (80% average purity, 
Supplemental Figure 7, A and B) and assessed MLKL activation. 
We consistently detected phospho-MLKL reactivity in endothelial 
cells isolated from TNF/zVAD-treated WT mice, but not in endo-
thelial cells isolated from Ripk1D138N/D138N mice (Figure 6E). We were 
unable to detect phospho-MLKL reactivity in endothelial cells 
isolated from TNF-treated mice, where endothelial breaks were 
observed only in half the mice examined (Figure 6D). Although 
unclear in the TNF shock model, TNF/zVAD-induced shock is 
mediated by RIPK1-dependent liver endothelial cell necroptosis.
Discussion
Here we demonstrate that the resistance of RIPK1 kinase–inactive 
mice to TNF- and TNF/zVAD-induced shock is not due to hemato-
poietic cells and/or cytokine storm, but rather due to lack of endo-
thelial cell necroptosis, which prevents breaks in the vascular endo-
thelium, activation of the clotting cascade, and organ damage. Our 
results provide genetic evidence that RIPK1 kinase activity medi-
ates endothelial cell necroptosis during TNF/zVAD-induced shock.
Cytokines such as IL-1β and IL-17α, and both apoptotic and 
necroptotic cell death, have been implicated in TNF-induced 
lethality (21, 23, 45–47). As reported previously in Nec-1–treated 
WT mice and Ripk3–/– mice (23), we found cytokine/chemokine 
induction to be normal in TNF-treated Ripk1D138N/D138N mice; howev-
er, these mice failed to sustain cytokine levels in response to TNF 
administration. Interestingly, we show that TNF/zVAD-induced 
shock augmented the proinflammatory response in WT, but not 
Ripk1D138N/D138N, mice (Figure 1B), supporting the notion that necro-
ptosis amplifies proinflammatory signaling and exacerbates organ 
injury. Multiple studies have shown that RIPK3 deficiency or phar-
macologic inhibition of RIPK1 kinase activity decreases serum 
levels of DAMPs, such as mitochondrial DNA, or markers of organ 
injury, such as creatinine kinase, aspartate aminotransferase, or 
lactate dehydrogenase (23, 48, 49). Furthermore, DAMPs such as 
HMGB1 and extracellular histones, are elevated in the blood of 
SIRS and sepsis patients, where they have been thought to result 
in chronic TLR activation and tissue injury (50–52).
TNF/zVAD administration elevated IL-1β levels, which were 
not systemically increased with TNF treatment alone. Caspase-1– 
and caspase-1/11–deficient mice, but not IL-1β/18–deficient mice, 
are susceptible to TNF-induced shock, thereby excluding a prima-
ry role for caspase-1–mediated inflammasome activation in TNF 
shock (23, 46). Two recent reports have implicated MLKL activa-
tion in initiating inflammasome-mediated processing and release 
of IL-1β (53, 54), suggesting that necroptosis sensitization in TNF/
zVAD-induced shock and MLKL activation may contribute to 
increases in plasma IL-1β levels.
In addition to cell death signaling, RIPK1 kinase activity has 
been implicated in cytokine production in vitro (32–34), includ-
ing reduced transcription and production of CXCL1 in TNF/
zVAD-treated RIPK1 kinase–inactive Ripk1K45A/K45A BMDMs 
(22). In agreement with these recent reports, we found CXCL1, 
CXCL2, and IL-6 transcription and secretion impaired in vitro in 
TNF/zVAD-treated Ripk1D138N/D138N BMDMs (Supplemental Figure 
1), suggesting that reductions in the cytokine response in RIPK1 
RIPK1 kinase activity is not required for TNF-induced endotheli-
al activation in vitro (Supplemental Figure 5A). Endothelial cells 
upregulate neutrophil chemokines CXCL1 and CXCL2 in response 
to TNF stimulation (39). Thus, we examined CXCL1 and CXCL2 
expression and secretion, but failed to detect any significant dif-
ferences in endothelial chemokine production between WT and 
RIPK1 kinase–inactive endothelial cells (Supplemental Figure 5, 
A and B). We then assessed whether RIPK1 kinase activity influ-
enced endothelial cell activation in vivo. After TNF or TNF/zVAD 
administration, we isolated RNA from WT and Ripk1D138N/D138N lung 
or liver and examined adhesion molecule and chemokine expres-
sion levels. We detected significant reductions in Sele, Selp, and 
Cxcl2 expression in TNF- or TNF/zVAD-treated Ripk1D138N/D138N 
mice; however, no consistent differences were observed in Icam1 
or Vcam1 expression (Supplemental Figure 6, A and B). Although 
chemokine differences were less pronounced in TNF-treated liv-
ers, TNF/zVAD treatment resulted in significant increases in Cxcl2 
expression in WT compared with Ripk1D138N/D138N liver (Supplemen-
tal Figure 6B), perhaps reflective of increased plasma IL-1β and 
IL-17α levels (40–42). While decreased chemokine mRNA levels 
in Ripk1D138N/D138N lung and liver correlated with reduced neutrophil 
infiltration during TNF- and TNF/zVAD-induced shock (Figure 2, 
D and E), TNF- or TNF/zVAD-induced adhesion molecule upreg-
ulation in vivo did not appear to require RIPK1 kinase activity.
RIPK1 kinase activity mediates TNF/zVAD-induced liver endo-
thelial cell necroptosis. Since the kinase activity of RIPK1 was not 
required for endothelial cell activation, we hypothesized that RIPK1 
kinase–regulated endothelial cell death may be responsible for the 
increase in vascular permeability, coagulation, and organ damage 
observed in WT mice. To test whether endothelial cells undergo 
necroptotic death, we isolated primary lung endothelial cells from 
WT and Ripk1D138N/D138N mice and treated them with concentrations 
of TNF, Smac mimetic, and zVAD known to induce necroptosis in 
murine embryonic fibroblasts (43). Primary lung endothelial cells 
isolated from WT mice did not undergo TNF/Smac-induced apop-
tosis or TNF/zVAD-induced necroptosis, but were susceptible to 
necroptosis induced by TNF/Smac/zVAD treatment (Supplemen-
tal Figure 5C). In contrast, Ripk1D138N/D138N endothelial cells were 
resistant to TNF/Smac/zVAD-induced necroptosis (Supplemental 
Figure 5C). Collectively, these data demonstrate that RIPK1 kinase 
activity is required for TNF-induced endothelial necroptosis in 
vitro (Supplemental Figure 5C) and for increased vascular per-
meability in vivo (Figure 5), implicating RIPK1 kinase–dependent 
endothelial cell necroptosis in SIRS.
To examine this possibility, we stained liver sections with 
endomucin, an endothelial cell marker (44), after TNF or TNF/
zVAD administration (Figure 6D). In treated WT mice, we detect-
ed breaks in the endothelial barrier, indicating endothelial cell loss 
and/or detachment and increased permeability and extravasation 
of leukocytes into the interstitial space (Figure 6D). TNF/zVAD 
treatment induced endothelial detachment with evidence of leu-
kocyte adherence and translocation in all 3 WT mice examined, 
whereas these morphological changes were observed in 2 of 4 WT 
mice treated with TNF. These histopathologic findings were not 
evident in TNF- or TNF/zVAD-treated Ripk1D138N/D138N mice, where 
liver endothelial barrier integrity was maintained similarly to that 
in untreated mice (Figure 6D).
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apoptosis in TNF-induced lethality (23, 37, 46), caspase-8–mediated 
effects likely reflect its role or roles in inflammasome-independent 
IL-1β regulation and processing (56).
Although TNF shock is typically thought of as a sterile model of 
injury, several reports show a key role for intestinal barrier dysfunc-
tion and systemic spread of bacteria in the blood of TNF-treated 
mice (36, 37). While intestinal necroptosis was not addressed in the 
Newton study, the Villin-cre Ripk3fl/fl mice may be protected from 
hypothermia and increased cytokine levels because RIPK3-defi-
cient intestinal epithelial cells fail to undergo necroptosis, and con-
sequently, the intestinal epithelial barrier is maintained. We show 
that Ripk1D138N/D138N mice did not exhibit TNF-induced increases in 
intestinal permeability, and we did not detect spread of bacteria 
to peripheral organs, such as the liver or spleen. While breaches in 
the intestinal epithelium and entry of bacteria or bacterial products 
into the bloodstream may contribute to TNF-induced shock, our 
data demonstrate that the downstream effects of the host response 
converge on the vascular endothelium.
We found that TNF-resistant Ripk1D138N/D138N mice and WT→ 
Ripk1D138N/D138N chimeras did not exhibit increases in lung and liver 
vascular permeability or evidence of increased tissue factor expres-
sion and coagulation. Furthermore, in the TNF/zVAD model, vas-
cular barrier protection and an absence of coagulation, at least 
in the liver, correlated with an inability to detect phospho-MLKL 
reactivity in the RIPK1 kinase–inactive endothelium. Our results 
indicate that necroptosis contributes to barrier disruption and acti-
vation of the clotting cascade, as we found MLKL activation in liver 
endothelial cells isolated from TNF/zVAD-treated WT mice.
Although TNF and TNF/zVAD treatment increased plasma 
tissue factor levels (Figure 5D) and induced coagulation (Figure 
6, A and B), we detected fewer breaks in the liver endothelium of 
TNF-treated WT mice (Figure 6D). Consistent with this observa-
tion, we were unable to detect phospho-MLKL–reactive endothe-
lial cells in livers of TNF-treated mice (Supplemental Figure 8A). 
We hypothesized that TNF may stimulate RIPK1 kinase–depen-
dent apoptosis; however, cleaved caspase-3–reactive cells were not 
detected in TNF-treated liver sections by immunohistochemistry 
or by immunoblotting endothelial cell lysates from TNF-treated 
mice (Supplemental Figure 8, B and C), suggesting that apoptosis 
is not responsible for the vascular breaks. In contrast with TNF/
zVAD administration, in which hypothermia and lethality are rap-
id and fully penetrant in WT controls (ref. 21 and Figure 3), mice 
treated with TNF took longer to exhibit symptoms (hypothermia, 
inactivity, hunched posture) and were variable in their presenta-
tion at sacrifice, 8 hours after TNF administration. We speculate 
that our inability to detect phospho-MLKL–reactive endothelial 
cells in mice treated with TNF reflects this variability in presenta-
tion, and consequently, fewer endothelial breaks (Figure 6D) and 
potentially less endothelial cell necroptosis were induced follow-
ing TNF treatment for 8 hours compared with TNF/zVAD treat-
ment for 4 hours.
We also demonstrate that lung endothelial cells isolated from 
WT, but not Ripk1D138N/D138N, mice undergo necroptosis in vitro when 
treated with TNF, Smac, and zVAD, but not with TNF/zVAD only 
(Supplemental Figure 5C). This finding was unexpected, as TNF/
zVAD administration is sufficient to induce liver endothelial cell 
necroptosis in vivo (Figure 6E). The requirement for Smac mimet-
kinase–inactive mice are due to effects of RIPK1 kinase activity on 
cytokine production rather than necroptotic cell death. With the 
exception of CXCL2, however, cytokine/chemokine production at 
early time points is unaffected by a lack of RIPK1 kinase activity 
(Figures 1 and 4), demonstrating that, in vivo, RIPK1 kinase activ-
ity is not required for cytokine/chemokine induction in response 
to a high dose of TNF. Substantial reductions in plasma cytokine/
chemokine levels were observed in TNF-treated Ripk1D138N/D138N 
mice at 7 hours, consistent with the proinflammatory nature of 
necroptotic death. Additionally, Ripk1D138N/D138N→WT chimeras 
had elevated cytokine/chemokine levels in response to TNF/zVAD 
administration (Supplemental Figure 3), suggesting that RIPK1 
kinase activity does not regulate cytokine/chemokine expression 
when caspases are inhibited in vivo.
We found that 3 of 11 Ripk1D138N/D138N→WT chimeras recov-
ered from TNF/zVAD administration (Figure 3E), indicating that 
Ripk1D138N/D138N hematopoietic cells can contribute to protection. 
Our data suggest that optimal cytokine/chemokine induction 
requires necroptosis-competent (WT) hematopoietic and endo-
thelial cells (Figure 4A), leading us to speculate that DAMPs 
released by necroptotic endothelial cells feed back on WT hema-
topoietic cells to induce necroptosis and further amplify cytokine 
levels. Thus, Ripk1D138N/D138N hematopoietic cells may mediate 
recovery in Ripk1D138N/D138N→WT chimeras by failing to undergo 
necroptosis in response to DAMPs released by WT necroptotic 
endothelial cells. Alternatively, recovery may be mediated by the 
survival of Ripk1D138N/D138N hematopoietic cells and production of 
antiinflammatory cytokines that support barrier repair.
A caveat of our bone marrow chimera studies is that protected 
WT→Ripk1D138N/D138N mice retain radiation-resistant, tissue-resident 
Ripk1D138N/D138N macrophages such as Kupffer cells (KC) in the liver. 
KC associate with endothelial cells in the liver sinusoids and func-
tion to maintain liver homeostasis by surveying microbial products 
from the intestine. KC express TLRs and produce cytokines and 
chemokines in response to DAMPs or pathogen-associated molec-
ular patterns (PAMPs). Moreover, KC undergo necroptosis upon 
Listeria monocytogenes infection (55). Thus, Ripk1D138N/D138N KC may 
contribute to resistance to shock by failing to undergo necropto-
sis and/or produce cytokine/chemokines in response to microbial 
products or DAMPs released by necroptotic endothelial cells.
Although we detected decreases in cleaved caspase-3 positive 
intestinal epithelial cells in the ileum of TNF-treated Ripk1D138N/D138N 
mice, no significant differences in intestinal apoptosis were observed 
between TNF/zVAD-treated WT and Ripk1D138N/D138N mice (Supple-
mental Figure 4). Consistent with these data, executioner caspase-3 
or caspase-7 and TNFR1-mediated intestinal epithelial cell apoptosis 
do not appear to contribute to TNF-induced lethality (23, 37). Howev-
er, Newton et al. showed that, while there is evidence of slight hypo-
thermia in Ripk3–/– and Mlkl–/– mice in response to TNF, Ripk3–/– 
Casp8–/– and Mlkl–/– Casp8–/– double-knockout mice are completely 
protected from TNF-induced hypothermia and have significantly 
reduced serum cytokine and chemokine levels (47). Additionally, 
they showed that Casp8+/– and Villin-cre Ripk3fl/fl mice are largely 
protected from TNF-induced cytokine/chemokine expression and 
hypothermia, suggesting that caspase-8 contributes to lethality 
during TNF-induced shock (47). Since our data and others indicate 
no role for the caspase-1–mediated inflammasome or intestinal 
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Cytokine analysis. Plasma cytokines were measured using a 12-plex 
protein/peptide multiplex analysis (Luminex Technology) conducted 
by the National Mouse Metabolic Phenotyping Center at the Universi-
ty of Massachusetts Medical School. Cytokines and chemokines that 
were below the limit of detection were assigned a value of zero. Blood 
was collected via cardiac puncture in a heparinized needle and spun 
down to isolate plasma. The samples were stored at –80°C until anal-
ysis. Plasma tissue factor levels were determined by ELISA (R&D Sys-
tems). IL-6 (eBioscience), CXCL1, CXCL2, and CCL5 (R&D Systems) 
secretion by cultured primary cells was determined by ELISA.
Gene-expression analysis. Primary BMDMs were treated with 50 
ng/ml TNF (R&D Systems) or TNF and 50 μM zVAD (Enzo) for 2 or 
6 hours. Primary lung endothelial cells were treated with TNF (100 ng/
ml) for 1 or 4 hours. Total cellular RNA was isolated using an RNeasy 
Mini Kit (QIAGEN). Total lung or liver RNA was extracted with TRIzol 
(Life Technologies). cDNA was prepared using the SuperScript First-
Strand Synthesis System (Invitrogen). Quantitative real-time PCR was 
performed using Power SYBR Green PCR Master Mix (Applied Bio-
systems) and run on the AB7300 Detection System (Applied Biosys-
tems). Relative gene expression was normalized to β-actin and deter-
mined using the ΔΔCT method. The primer sequences used to amplify 
murine genes are listed in Supplemental Table 1.
Flow cytometry. Single-cell suspensions from blood, spleen, bone 
marrow, lung, and liver were stained with cell-surface antibodies for 
myeloid (Gr1, CD11b, CD11c, and Ly6c), lymphoid (CD4, CD8, and 
B220), and endothelial (CD31) markers. To distinguish between donor 
and host hematopoietic cells in the bone marrow reconstitution exper-
iments, anti-CD45.1 and anti-CD45.2 antibodies were used. DAPI 
(Molecular Probes) was used to distinguish between live and dead 
cells. All samples were run on a BD LSRII flow cytometer (BD Biosci-
ence) and analyzed using FlowJo software (Tree Star). A complete list 
of flow cytometry antibodies is provided in Supplemental Table 2.
Prothrombin time test. Blood was collected via cardiac puncture 
and mixed with 3.2% sodium citrate at a 9:1 ratio. Plasma was isolated 
and the test was conducted by IDEXX.
Vascular permeability assay. A 1% Evans blue (Sigma-Aldrich) solu-
tion was injected i.v. at 40 mg/kg 6 hours after mTNF-α administration. 
After 1 hour, the mice were sacrificed and perfused, and organs were 
dried overnight before homogenization in formamide (MilliporeSig-
ma). The amount of extracted Evans blue dye was assessed by spectro-
photometry at 620 nm on a Beckman Coulter DTX880 plate reader.
Intestinal permeability assay. Mice were orally gavaged with 100 
μl of 150 mg/kg FITC-dextran (M.W. 4000) beads (Sigma-Aldrich) 
2 hours after TNF administration. Six hours later, blood was drawn via 
cardiac puncture. The amount of FITC-dextran in plasma was mea-
sured on a Beckman Coulter DTX880 plate reader (excitation wave-
length, 488 nm; emission wavelength, 530 nm).
Histology and immunohistochemistry. Livers were fixed in 2% para-
formaldehyde (Fisher Scientific). Samples were embedded in paraf-
fin, and H&E staining was done on 8 μm–thick sections according to 
standard protocols. Cleaved caspase-3 staining was done on 6 μm–
thick sections at 1:100 dilution of cleaved caspase-3 antibody (catalog 
9661, Cell Signaling Technology) according to standard protocols. For 
endomucin staining, 3 μm–thick liver sections were processed through 
xylene and rehydrated through an ethanol gradient prior to immersion 
in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 
6) and antigen retrieval was done using a 2100 Antigen Retriever. Sec-
ic to induce endothelial necroptosis in vitro may reflect increased 
cellular pools of cIAP1/2 or XIAP in lung versus liver endothelial 
cells or simply indicate that TNF/zVAD concentrations achieved 
in vivo are not accurately modeled in vitro.
Many septic patients have impaired endothelial barrier func-
tion and exhibit edema, coagulation abnormalities, and decreased 
levels or dysfunctional activation of anticoagulants. The most 
promising clinical trials have focused on combining antiinflam-
matory and anticoagulant agents, such as activated protein C 
or thrombomodulin (57). Recent advances focus on methods to 
strengthen the vascular endothelium and modulate its response to 
proinflammatory cytokine levels. In several models of LPS endo-
toxemia or cecal ligation and puncture, enhanced vascular stabil-
ity dramatically increased mouse survival, even though no reduc-
tions in the proinflammatory cytokine response were observed 
(58, 59). Similarly, we demonstrate that chimeric mice susceptible 
to TNF-induced shock exhibited increased vascular permeability 
and coagulation even when proinflammatory cytokine levels were 
not sustained (Figure 4A and Figure 5, E and F). We provide evi-
dence that Ripk1D138N/D138N liver endothelial cells failed to exhibit 
MLKL activation and undergo necroptosis (Figure 6E), thereby 
maintaining an intact vasculature that protects RIPK1 kinase–
inactive mice from TNF/zVAD-induced lethality. Interestingly, 
RIPK3 plasma levels are significantly increased in nonsurvivors of 
sepsis (60), suggesting that endothelial cell necroptosis may con-
tribute to lethality in both SIRS and sepsis patients. Ripk1D138N/D138N, 
Ripk3–/–, and Mlkl–/– mice have been examined in mouse models of 
sepsis, and although the results generated using the cecal ligation 
and puncture model are conflicting (15, 23, 61), we and others find 
Ripk1D138N/D138N mice susceptible to LPS administration (ref. 47 and 
M. Zelic and M.A. Kelliher, unpublished observations), indicating 
that necroptosis may not be a critical factor in sepsis. The role of 
necroptosis in shock and sepsis needs to be explored further, but 
our results demonstrate that RIPK1 kinase inhibitors may show 
promise in ameliorating or preventing inflammatory vascular 
injury and SIRS.
Methods
Mice. Ripk1D138N/D138N mice on a C57BL/6 background were described 
previously (21). For bone marrow transplantation studies, recipient 
C57BL/6 CD45.1 or CD45.2 (WT or Ripk1D138N/D138N) mice received 
11 Gy of total body irradiation in a split dose (5.5 Gy/dose) using a 
Cesium-137 irradiator, with a 4-hour rest between doses. Irradiated 
recipients were reconstituted by i.v. injection of 2 × 106 WT (CD45.1 
or CD45.2) or Ripk1D138N/D138N (CD45.2) bone marrow cells. Recipients 
were maintained on medicated water for 1 month. Cheek bleeds 
were performed after 4 and 8 weeks to assess reconstitution efficien-
cy by flow cytometry.
TNF-induced shock experiments. Sex-matched male WT and 
Ripk1D138N/D138N littermates were injected i.v. with 9 μg mTNF-α (Cell Sci-
ences) alone or in combination with 16.7 mg/kg zVAD-fmk (Bachem) 
unless noted otherwise. Body temperature and survival were moni-
tored every few hours. Mice were used between 8 and 12 weeks of age. 
For ex vivo analyses, mice were typically sacrificed after 4 (TNF/zVAD) 
or 8 hours (TNF). Reconstituted mice were injected with mTNF-α and 
zVAD-fmk 2 months after reconstitution. When littermate controls 
were not used, sex- and age-matched mice were cohoused.
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Immunoblotting. Isolated liver endothelial cells were lysed in RIPA 
buffer (150 mM NaCl, 50 mM Tris-HCl [pH 7.5], 1% NP40, 0.25% 
deoxycholate, 0.1% SDS, 1 mM EDTA) supplemented with protease 
inhibitors (Roche Applied Science), sodium orthovanadate (1 mM), 
PMSF (1 mM), and DTT (1 mM). Total protein was run on a 10% SDS-
PAGE gel, transferred to a nitrocellulose membrane (Invitrogen), 
and probed with antibodies to phospho-MLKL (ab196436, Abcam), 
MLKL (gift from Jiahuai Han, Xiamen University, Xiamen, China, 
and AP14272b, Abgent), caspase-3 (catalog 9662, Cell Signaling), and 
Erk1/2 (catalog 9102, Cell Signaling). Membranes were developed 
with Clarity Western ECL Substrate (Bio-Rad).
Cell viability. For apoptosis and necroptosis assays, cultured lung 
endothelial cells were pretreated with 1 μM Smac mimetic (ChemieTek) 
or 20 μM zVAD-fmk (Enzo) prior to adding TNF (10 ng/ml). Metabol-
ic activity was assayed after 20 hours by the addition of MTS reagent 
(CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega) 
and measured using a Beckman Coulter DTX880 plate reader. Absor-
bance values at 535 nm were normalized to Smac mimetic control.
Statistics. Data are presented as mean ± SEM. Statistical analy-
ses were performed using GraphPad Prism software, version 7.02. 
Kaplan-Meier survival curves were analyzed using a log-rank test 
with a 95% CI. Statistical analysis was performed using the unpaired 
2-tailed Student’s t test or 1-way ANOVA or 2-way ANOVA with post 
hoc Tukey’s test.
Study approval. All animal procedures used in this study were 
approved by the University of Massachusetts Medical School IACUC 
and conducted in accordance with university guidelines.
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tions were incubated for 1 hour at room temperature (RT) in blocking 
solution (1% rabbit serum, 1% BSA, 0.3% Triton-X 100 in PBS) and 
then kept in a primary antibody mix (Endomucin, 1:200, Santa Cruz 
Biotechnology Inc., sc-65495; in 2.5% rabbit serum in PBS) overnight 
at 4°C. Rat secondary antibody was used for 1 hour at RT (Vector Bioti-
nylated Anti-Rat IgG). Sections were developed using the Vectastain 
Elite ABC Kit and the DAB Peroxidase Substrate Kit according to the 
manufacturer’s instructions (Vector Laboratories) before counterstain-
ing with hematoxylin and mounting with VECTASHIELD Dry Mount-
ing Media. All images were acquired using a Nikon Eclipse 80i micro-
scope. To quantify the percentage of clotting in liver blood vessels, 8 
random fields at a ×20 field of view were counted per mouse. To quan-
tify the number of cleaved caspase-3–positive cells in the intestines or 
liver, 10 random fields at ×40 field of view were counted per mouse.
Primary cell cultures. BMDMs were generated by culturing bone 
marrow cell suspensions in 20% conditioned media from L929 cells 
for 7 days. On day 7, adherent cells were replated in 6-well plates for 
mRNA experiments (2 × 106 cells per well) or in 96-well plates for 
ELISA assays (2 × 105 cells per well). Mouse lungs were digested in 25 
ml of 1 mg/ml collagenase at 37°C for an hour. After sequential filter-
ing through a 100 μm and 40 μm cell strainer, the cell suspension was 
plated on a gelatin-coated T75 flask and the cells were incubated for 
4 to 6 days until reaching confluence. Cells were grown in endothe-
lial cell media containing low-glucose DMEM/F-12 with 20% FBS, 
1% l-glutamine, 1% penicillin/streptomycin, 100 μg/ml heparin, and 
50 μg/ml endothelial cell growth supplement (Biomedical Technol-
ogies Inc.). To immunoselect endothelial cells, confluent T75 flasks 
were incubated with CD-31 (PECAM-1, catalog 553369, BD Biosci-
ences) and CD102-coated (ICAM-2, catalog 553325, BD Biosciences) 
Dynabeads on ice for 20 minutes. Using a magnetic separator, bead-
bound cells were recovered and washed 3 times with PBS. Endothelial 
cells were plated on gelatin-coated T25 flasks and expanded.
Liver endothelial cell isolation. Mice were perfused with PBS, and 
livers were minced with a razor blade on ice and shaken for 30 minutes 
at 37°C in 1 mg/ml collagenase. The suspension was filtered through a 
100 μm strainer and spun for 5 minutes at 50 g to separate out hepato-
cytes. The supernatant was spun again for 5 minutes at 60 g before the 
nonparenchymal cell fraction in the supernatant was pelleted at 700 
g for 10 minutes. After red blood cell lysis, the nonparenchymal liver 
cell fraction was depleted of CD45+ cells before enriching for CD146+ 
endothelial cells with MACS MicroBeads, according to the manufac-
turer’s instructions (Miltenyi Biotec). Purity was checked by FACS, and 
recovered cells were snap-frozen to use for Western blot.
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